| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cichoriin targets viral replication mechanisms, specifically showing activity against SARS-CoV-2. As a coumarin glycoside, it may interact with viral enzymes or host factors involved in the viral life cycle. The compound exhibits potential in inhibiting viral replication. Its mechanism may involve interference with viral entry, replication, or assembly processes. Further studies are needed to fully elucidate the specific molecular targets and pathways through which Cichoriin exerts its antiviral effects. The compound's natural origin from chicory suggests potential for development as a natural product-based antiviral agent.
|
|---|---|
| ln Vitro |
Cichoriin is an active compound against SARS-CoV-2, demonstrating potential antiviral activity. It exhibits potential in inhibiting viral replication. As a coumarin derivative, it may also possess other biological activities including antioxidant and anti-inflammatory properties typical of this class of compounds. The compound's activity against SARS-CoV-2 suggests it may be a potential candidate for researching severe COVID-19. Further detailed in vitro studies are needed to determine its IC50 and mechanism of action against viral replication.
|
| ln Vivo |
In vivo studies for Cichoriin have not been extensively documented in the available literature. The compound is an active compound against SARS-CoV-2 and may be a potential candidate in researching severe COVID-19. As a natural product from chicory, it has a history of use in traditional medicine, suggesting potential tolerability. However, systematic in vivo efficacy and safety studies in animal models are needed to validate its therapeutic potential for COVID-19 and other indications. The compound exhibits potential in inhibiting viral replication.
|
| Enzyme Assay |
For antiviral activity assays, Vero E6 or other appropriate cell lines are infected with SARS-CoV-2 and treated with Cichoriin at various concentrations. Viral replication is assessed by qRT-PCR to measure viral RNA levels in culture supernatants, or by plaque reduction assays to determine the number of infectious viral particles. Cytotoxicity is assessed in parallel using MTT or CellTiter-Glo assays to determine the selectivity index. For enzyme inhibition studies, purified viral proteases or polymerases are incubated with the compound and appropriate substrates, and activity is measured by fluorometric or colorimetric methods.
|
| Cell Assay |
For antiviral activity evaluation, Vero E6 or other susceptible cell lines are cultured in appropriate media and infected with SARS-CoV-2 at a suitable multiplicity of infection. Cells are treated with Cichoriin at various concentrations (typically 0.1-100 μM) for 24-48 hours post-infection. Viral RNA is extracted from culture supernatants and quantified by qRT-PCR using primers specific for SARS-CoV-2 genes. Alternatively, plaque reduction assays are performed by overlaying infected cells with agarose containing the compound and counting plaques after staining. Cytotoxicity is assessed in uninfected cells treated with the same compound concentrations.
|
| Animal Protocol |
For in vivo antiviral efficacy studies, appropriate animal models (e.g., transgenic mice expressing human ACE2 or hamster models) would be infected with SARS-CoV-2 and administered Cichoriin orally or intraperitoneally. Viral load in lung tissues and other organs would be measured by qRT-PCR, and histopathological analysis would assess lung inflammation and damage. Survival and body weight would be monitored. However, detailed in vivo protocols for Cichoriin have not been extensively reported in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cichoriin have not been fully characterized in the available literature. As a glycosylated coumarin with a molecular weight of 340.28, it is expected to have moderate water solubility. The compound is typically stored as powder at 2-8°C for up to 2 years, and in solvent at -20°C for 1 month or -80°C for 6 months. Comprehensive pharmacokinetic studies including bioavailability, half-life, protein binding, and tissue distribution are needed to fully understand its ADME properties.
|
| Toxicity/Toxicokinetics |
Cichoriin is a natural product and research compound intended for laboratory use only. As an active compound against SARS-CoV-2, it may be a potential candidate in researching severe COVID-19. The compound exhibits potential in inhibiting viral replication. As a coumarin derivative from chicory, it has a history of use in traditional medicine. However, comprehensive toxicological studies have not been documented. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Chicorinin is a glycoside belonging to the coumarin class of compounds. It has been reported to be found in ash trees, soybeans, and other organisms with relevant data.
Cichoriin is a coumarin derivative (7-O-glucosyl-esculetin) isolated from Cichorium intybus L., with molecular formula C15H16O9 and molecular weight 340.28. It is an active compound against SARS-CoV-2 and may be a potential candidate for researching severe COVID-19. The compound exhibits potential in inhibiting viral replication. It is a natural product with potential antiviral applications. Cichoriin is for research use only and has not been approved for clinical applications. Storage at 2-8°C as powder or -20°C/-80°C in solvent is recommended. |
| Molecular Formula |
C15H16O9
|
|---|---|
| Molecular Weight |
340.28
|
| Exact Mass |
340.079
|
| CAS # |
531-58-8
|
| PubChem CID |
442101
|
| Appearance |
White to off-white solid powder
|
| Density |
1.679±0.06 g/cm3(Predicted)
|
| Boiling Point |
697.7±55.0 °C(Predicted)
|
| Melting Point |
213-215 °C
|
| LogP |
-0.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
495
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=O)OC2=CC(=C(C=C21)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
|
| InChi Key |
WNBCMONIPIJTSB-TVKJYDDYSA-N
|
| InChi Code |
InChI=1S/C15H16O9/c16-5-10-12(19)13(20)14(21)15(24-10)23-9-4-8-6(3-7(9)17)1-2-11(18)22-8/h1-4,10,12-17,19-21H,5H2/t10-,12-,13+,14-,15-/m1/s1
|
| Chemical Name |
6-hydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (293.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9388 mL | 14.6938 mL | 29.3876 mL | |
| 5 mM | 0.5878 mL | 2.9388 mL | 5.8775 mL | |
| 10 mM | 0.2939 mL | 1.4694 mL | 2.9388 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
